347 related articles for article (PubMed ID: 35228751)
1. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Lee KA; Thomas AM; Bolte LA; Björk JR; de Ruijter LK; Armanini F; Asnicar F; Blanco-Miguez A; Board R; Calbet-Llopart N; Derosa L; Dhomen N; Brooks K; Harland M; Harries M; Leeming ER; Lorigan P; Manghi P; Marais R; Newton-Bishop J; Nezi L; Pinto F; Potrony M; Puig S; Serra-Bellver P; Shaw HM; Tamburini S; Valpione S; Vijay A; Waldron L; Zitvogel L; Zolfo M; de Vries EGE; Nathan P; Fehrmann RSN; Bataille V; Hospers GAP; Spector TD; Weersma RK; Segata N
Nat Med; 2022 Mar; 28(3):535-544. PubMed ID: 35228751
[TBL] [Abstract][Full Text] [Related]
2. Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma.
Wind TT; Gacesa R; Vich Vila A; de Haan JJ; Jalving M; Weersma RK; Hospers GAP
Melanoma Res; 2020 Jun; 30(3):235-246. PubMed ID: 31990790
[TBL] [Abstract][Full Text] [Related]
3. TIGIT
Tsakmaklis A; Farowski F; Zenner R; Lesker TR; Strowig T; Schlößer H; Lehmann J; von Bergwelt-Baildon M; Mauch C; Schlaak M; Knuever J; Schweinsberg V; Heinzerling LM; Vehreschild MJGT
BMC Cancer; 2023 Nov; 23(1):1160. PubMed ID: 38017389
[TBL] [Abstract][Full Text] [Related]
4. The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman DD; Hurd D; Davar D
Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
[TBL] [Abstract][Full Text] [Related]
5. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
Thompson NA; Stewart GD; Welsh SJ; Doherty GJ; Robinson MJ; Neville BA; Vervier K; Harris SR; Adams DJ; Dalchau K; Bruce D; Demiris N; Lawley TD; Corrie PG
BMC Cancer; 2022 Jan; 22(1):99. PubMed ID: 35073853
[TBL] [Abstract][Full Text] [Related]
6. Gut microbial structural variation associates with immune checkpoint inhibitor response.
Liu R; Zou Y; Wang WQ; Chen JH; Zhang L; Feng J; Yin JY; Mao XY; Li Q; Luo ZY; Zhang W; Wang DM
Nat Commun; 2023 Nov; 14(1):7421. PubMed ID: 37973916
[TBL] [Abstract][Full Text] [Related]
7. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
9. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
10. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma.
Coleman S; Xie M; Tarhini AA; Tan AC
Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709
[TBL] [Abstract][Full Text] [Related]
11. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
12. Physiologic colonic uptake of
Cvetkovic L; Régis C; Richard C; Derosa L; Leblond A; Malo J; Messaoudene M; Desilets A; Belkaid W; Elkrief A; Routy B; Juneau D
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1550-1559. PubMed ID: 33128571
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
Björk JR; Bolte LA; Maltez Thomas A; Lee KA; Rossi N; Wind TT; Smit LM; Armanini F; Asnicar F; Blanco-Miguez A; Board R; Calbet-Llopart N; Derosa L; Dhomen N; Brooks K; Harland M; Harries M; Lorigan P; Manghi P; Marais R; Newton-Bishop J; Nezi L; Pinto F; Potrony M; Puig S; Serra-Bellver P; Shaw HM; Tamburini S; Valpione S; Waldron L; Zitvogel L; Zolfo M; de Vries EGE; Nathan P; Fehrmann RSN; Spector TD; Bataille V; Segata N; Hospers GAP; Weersma RK
Nat Med; 2024 Mar; 30(3):785-796. PubMed ID: 38365950
[TBL] [Abstract][Full Text] [Related]
14. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
Hakozaki T; Richard C; Elkrief A; Hosomi Y; Benlaïfaoui M; Mimpen I; Terrisse S; Derosa L; Zitvogel L; Routy B; Okuma Y
Cancer Immunol Res; 2020 Oct; 8(10):1243-1250. PubMed ID: 32847937
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
Cass SH; Tobin JWD; Seo YD; Gener-Ricos G; Keung EZ; Burton EM; Davies MA; McQuade JL; Lazar AJ; Mason R; Millward M; Sandhu S; Khoo C; Warburton L; Guerra V; Haydon A; Dearden H; Menzies AM; Carlino MS; Smith JL; Mollee P; Burgess M; Mapp S; Keane C; Atkinson V; Parikh SA; Markovic SN; Ding W; Call TG; Hampel PJ; Long GV; Wargo JA; Ferrajoli A
Ann Oncol; 2023 Sep; 34(9):796-805. PubMed ID: 37414216
[TBL] [Abstract][Full Text] [Related]
16. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiome for predicting immune checkpoint blockade-associated adverse events.
Hu M; Lin X; Sun T; Shao X; Huang X; Du W; Guo M; Zhu X; Zhou Y; Tong T; Guo F; Han T; Wu X; Shi Y; Xiao X; Zhang Y; Hong J; Chen H
Genome Med; 2024 Jan; 16(1):16. PubMed ID: 38243343
[TBL] [Abstract][Full Text] [Related]
18. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
19. A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors.
Shaikh FY; White JR; Gills JJ; Hakozaki T; Richard C; Routy B; Okuma Y; Usyk M; Pandey A; Weber JS; Ahn J; Lipson EJ; Naidoo J; Pardoll DM; Sears CL
Clin Cancer Res; 2021 May; 27(9):2571-2583. PubMed ID: 33593881
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade.
Gorgulho J; Roderburg C; Beier F; Bokemeyer C; Brümmendorf TH; Luedde T; Loosen SH
Front Immunol; 2023; 14():1206953. PubMed ID: 37705980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]